Navigation Links
Dr. Mahdi B. Fawzi Joins Warner Chilcott as President, Global Research and Development
Date:10/20/2009

ARDEE, Ireland, Oct. 20 /PRNewswire-FirstCall/ -- Warner Chilcott plc (Nasdaq: WCRX) announced today that Dr. Mahdi Fawzi has joined the company as President, Global Research and Development. He joins Warner Chilcott from Wyeth Pharmaceuticals, where he was responsible for directing global preclinical development activities.

"Dr. Fawzi is joining Warner Chilcott during a very exciting period in the company's history," said Roger Boissonneault, Warner Chilcott's President and Chief Executive Officer. "We look forward to the contributions he will make based on his experience and numerous achievements along the spectrum of R&D activities, from pre-development to life cycle management and commercial phases of drug development."

Prior to joining Warner Chilcott, Dr. Fawzi spent nearly 15 years with Wyeth, most recently as Executive Vice President, Preclinical Development where he led the development and launch of numerous new drugs. During his tenure, he was selected as one of four finalists for the Pharmaceutical Executive of the Year award. Prior to Wyeth, Dr. Fawzi also held positions with Warner Lambert, The Procter & Gamble Company and Pfizer, Inc.

Dr. Fawzi received his Bachelor of Science in Pharmacy from the University of Bagdad and his Masters and Doctorate in Pharmaceutical Chemistry from the University of Michigan.

The Company

Warner Chilcott is a leading specialty pharmaceutical company currently focused on the women's healthcare and dermatology segments of the U.S. pharmaceuticals market. It is a fully integrated company with internal resources dedicated to the development, manufacturing and promotion of its products. WCRX-G

SOURCE Warner Chilcott plc


'/>"/>
SOURCE Warner Chilcott plc
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. The Medco Foundation Joins With the Entertainment Industry Foundation to Give Health a Hand to Communities in Need
2. Dilon Diagnostics Joins Forces With Philips for Womens Health Solutions
3. Amarex Clinical Research Selects OmniComm Systems to Provide eClinical Solutions for Phase III Medical Device Study and Joins OmniComms CRO Preferred Program
4. UPCI Joins ExCell Research Study Using Stem Cells for Leukemia and Lymphoma Patients
5. Chuck Panozzo, Founder of Rock Band Styx, Joins GeoVax Labs, Inc. as an Advocate for Its HIV/AIDS Vaccine
6. BARC Central Laboratory Joins Alzheimers Association Research Roundtable
7. Richard E.T. Smith, Ph.D. Joins Pharmasset as Vice President of Investor Relations and Corporate Communications
8. Photos: Sentara Joins 4 U.S. Hospitals in International TARGIT Breast Cancer Trial
9. Leading Cardiologist Joins Ontario Research Firm to Conduct New Clinical Trial on the Effect of Pantethine on Cholesterol Levels
10. Vincent W. Renz Joins NewCardio as President
11. Judith Quinlan Joins Cytel as Vice President, Adaptive Trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... MEMPHIS, Tenn. , Feb. 11, 2016 ... a promising new treatment method at West Cancer ... low intensity electric fields to inhibit cancer cell replication ... therapy in more than a decade to show a ... adult Glioblastoma Multiforme (GBM) patients. Currently, West Cancer Center ...
(Date:2/11/2016)... -- Jeffrey Zucker , vice president of ... at this year,s Summit for Clinical Operations Executives (SCOPE), being ... Miami, FL. Zucker will discuss how sponsors can ... SCOPE,s "Improving Site Study Activation and Performance" portion of the ... at 11:05 a.m. --> --> ...
(Date:2/11/2016)... Feb. 11, 2016  Community pharmacists can help improve ... the pharmacy through a custom-built medication synchronization program, Cardinal ... and owner at Schieber Family Pharmacy in ... a lot of patients enrolled in this medication synchronization ... a win for the patient, and it,s a win ...
Breaking Medicine Technology:
(Date:2/11/2016)... ... 2016 , ... PharmMD CEO Robert Yeager announced ... on contract negotiations, corporate strategy and healthcare data law. Additional responsibilities will include ... data breaches for the Part D Star Rating improvement and Medication Therapy Management ...
(Date:2/11/2016)... Island, NY (PRWEB) , ... February 11, 2016 ... ... has enhanced and updated its hallmark resource, Infusion Therapy Standards of Practice, to ... leader in vein illumination with an estimated 85% share of the market, facilitates ...
(Date:2/11/2016)... ... , ... The annual list showcases the 20 Most Promising SharePoint Solution Providers ... and commitment to the SharePoint ecosystem. A panel of experts and members of CIOReview’s ... recognize and promote technology entrepreneurship. , The survey was made at the end ...
(Date:2/11/2016)... ... February 11, 2016 , ... ... ergoFET force gauges used in physical therapy, occupational therapy and sports medicine clinics, ... resistance cord exercise and therapy, introduces its new microFET Digital Pinch Gauge. ...
(Date:2/11/2016)... (PRWEB) , ... February 11, 2016 , ... ... coverage results in significantly higher rates of several common cancer screenings, especially among ... in better outcomes and survival rates. , The study,“What Does Medicaid Expansion ...
Breaking Medicine News(10 mins):